HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herholz, K. Articles by Comar, D. Search for Related Content PubMed PubMed Citation Articles by Herholz, K. Articles by Comar, D.

Comparability of FDG PET Studies in Probable Alzheimer's Disease

Max-Planck-Institut für Neurologische Forschung, Cologne, Germany
Istituto di Technologie Biomediche Avanzate, Hospital San Raffaele, Medizina Nucleare, Milan, Italy
Universié de Liège, Centre de Recherches du Cyclotron, Liège, Belgium

Correspondence: For correspondence and reprints contact: Dr. Karl Herholz, Max-Planck-Institut für neurologische Forschung, Gleusler Str. 50, W-5000 Köln 41, Germany.

ABSTRACT

Results of studies with positron emission tomography (PET) of ¹⁸F-2-fluoro-2-deoxy-D-glucose (FDG) in patients with probable Alzheimer's disease (AD) were compared among three European centers with different PET scanners (in-plane resolution ranging between 6.75 mm and 9.2 mm). A ratio of glucose metabolism in the most typically affected regions over the least typically affected regions was calculated to quantitatively analyze the characteristic pattern of AD. Diagnostic accuracy of this composite ratio was high (95.8%) and was superior to that of most ratios derived from single regions. Correspondingly, there was a consistent, highly significant difference between patients (mean ratio 0.77 ± 0.11) and normals (mean 0.99 ± 0.04) without significant differences among laboratories. Possible small effects of rate constant variation and region size were analyzed by computer simulation. The results demonstrate that a common investigation protocol may yield FDG PET data in different laboratories that are closely comparable in spite of differences between scanners and imaging equipment.

This article has been cited by other articles:

				K. Ishii, T. Soma, A. K. Kono, K. Sofue, N. Miyamoto, T. Yoshikawa, E. Mori, and K. Murase Comparison of Regional Brain Volume and Glucose Metabolism Between Patients with Mild Dementia with Lewy Bodies and Those with Mild Alzheimer's Disease J. Nucl. Med., May 1, 2007; 48(5): 704 - 711. [Abstract] [Full Text] [PDF]

				M. B. Patwardhan, D. C. McCrory, D. B. Matchar, G. P. Samsa, and O. T. Rutschmann Alzheimer Disease: Operating Characteristics of PET-- A Meta-Analysis Radiology, April 1, 2004; 231(1): 73 - 80. [Abstract] [Full Text] [PDF]

				B. Matthews, E. R. Siemers, and P. D. Mozley Imaging-Based Measures of Disease Progression in Clinical Trials of Disease-Modifying Drugs for Alzheimer Disease Am J Geriatr Psychiatry, April 1, 2003; 11(2): 146 - 159. [Abstract] [Full Text] [PDF]

				K. Herholz, H. Schopphoff, M. Schmidt, R. Mielke, W. Eschner, K. Scheidhauer, H. Schicha, W.-D. Heiss, and K. Ebmeier Direct Comparison of Spatially Normalized PET and SPECT Scans in Alzheimer's Disease J. Nucl. Med., January 1, 2002; 43(1): 21 - 26. [Abstract] [Full Text] [PDF]

				S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]

				J. M. Hoffman, K. A. Welsh-Bohmer, M. Hanson, B. Crain, C. Hulette, N. Earl, and R. E. Coleman FDG PET Imaging in Patients with Pathologically Verified Dementia J. Nucl. Med., November 1, 2000; 41(11): 1920 - 1928. [Abstract] [Full Text] [PDF]